anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The long COVID (coronavirus disease), a multisystemic condition following severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection, is one of the widespread problems. Some of its symptoms affect the nervous system and resemble symptoms of Alzheimer's disease (AD)-a neurodegenerative condition caused by the accumulation of amyloid beta and hyperphosphorylation of tau proteins. Multiple studies have found dependence between these two conditions. Patients with Alzheimer's disease have a greater risk of SARS-CoV-2 infection due to increased levels of angiotensin-converting enzyme 2 (ACE2), and the infection itself promotes amyloid beta generation which enhances the risk of AD. Also, the molecular pathways are alike-misregulations in folate-mediated one-carbon metabolism, a deficit of Cq10, and disease-associated microglia. Medical imaging in both of these diseases shows a decrease in the volume of gray matter, global brain size reduction, and hypometabolism in the parahippocampal gyrus, thalamus, and cingulate cortex. In some studies, a similar approach to applied medication can be seen, including the use of amino adamantanes and phenolic compounds of rosemary. The significance of these connections and their possible application in medical practice still needs further study but there is a possibility that they will help to better understand long COVID.
Patients watch an educational video about Mohs surgery before their surgery, a video about wound care after the surgery and receive text messages about wound care on days 1-5 after the surgery. Patients also receive instructions to reduce movement and use a Fitbit activity tracker. Beginning 48 hours after surgery, patients are instructed to apply petroleum jelly BID to the wound area.
<P>PROBLEM TO BE SOLVED: To provide Apo-2 ligand variant polypeptides.  <P>SOLUTION: The invention relates to the Apo-2 ligand variants including one or a plurality of amino acid substitutions in the native sequence of the Apo-2 ligand. The Apo-2 ligand variant may include substitution with cysteine, lysine and serine. An isolated nucleic acid containing a nucleotide sequence encoding the Apo-2 ligand variant, a vector comprising such nucleic acid and a host cell including the vector are provided. A preparation including the Apo-2 ligand variant polypeptides pharmaceutically acceptable and useful for inducing or stimulating apoptosis in cancer cell of mammal, or treating immune-related disease such as arthritis, multiple sclerosis.  <P>COPYRIGHT: (C)2008,JPO&INPIT
A preparation method of a dampness removing and granulation promoting powder for treating wound ulceration solves the defects of the background technology, namely poor treatment effect of healing wounds with skin ulceration, pus and bleeding and no wound healing, and is not easy to seal. The method is characterized in that: selecting 50g of fructus forsythiae, 50g of radix scutellariae, 50g of cortex phellodendri, 50g of green fumigation, 50g of angelica, 70g of talcum and 50g of amber, grinding the materials into powder, sieving the powder, mixing the powder and the powder, and applying the powder to an affected part. The advantages are that: has excellent effect after being used in a large number of clinics. Has good anti-inflammation and detumescence effect on wounds, so the wound healing effect is good and the wounds heal quickly. The dampness removing and tissue regeneration promoting powder for treating wound fester can treat the fester of the patient in a short time, relieves and reduces the pain of the patient and the medical expense of the patient; the ulcer of any part of the body is not well treated for a long time, and the dampness removing and tissue regeneration promoting powder for treating the wound ulcer can be used for treating both diseases. For treating wound ulceration.
An 8-week remotely-delivered pain self-management program tailored to older adults that have been experiencing pain for at least three months. Participants randomized to the Online Group will receive access to the course on the computer (online). A researcher will act as a guide who provides general support and encouragement, as opposed to a clinician who would offer comprehensive therapy. The guide will aim to contact participants weekly via telephone for approximately 5 to 10 minutes.
BACKGROUND: The aim of this study was to evaluate commonly assumed causal relationships between body mass index (BMI), gestational weight gain (GWG), and adverse pregnancy outcomes, which have formed the basis of guidelines and interventions aimed at limiting GWG in women with overweight or obesity. We explored relationships between maternal BMI, total GWG (as a continuous variable and as 'excessive' GWG), and pregnancy outcomes (including infant birthweight measures and caesarean birth).
METHODS: Analysis of individual participant data (IPD) from the i-WIP (International Weight Management in Pregnancy) Collaboration, from randomised trials of diet and/or physical activity interventions during pregnancy reporting GWG and maternal and neonatal outcomes. Women randomised to the control arm of 20 eligible randomised trials (4370 of 8908 participants) from the i-WIP dataset of 36 randomised trials (total 12,240 women). The main research questions were to characterise the relationship between maternal BMI and (a) total GWG, (b) the risk of 'excessive' GWG (using the Institute of Medicine's guidelines), and (c) adverse pregnancy outcomes as mediated via GWG versus other pathways to determine the extent to which the observed effect of maternal BMI on pregnancy outcomes is mediated via GWG. We utilised generalised linear models and regression-based mediation analyses within an IPD meta-analysis framework.
RESULTS: Mean GWG decreased linearly as maternal BMI increased; however, the risk of 'excessive' GWG increased markedly at BMI category thresholds (i.e. between the normal and overweight BMI category threshold and between the overweight and obese BMI category threshold). Increasing maternal BMI was associated with increased risk of all pregnancy outcomes assessed; however, there was no evidence that this effect was mediated via effects on GWG.
CONCLUSIONS: There is evidence of a meaningful relationship between maternal BMI and GWG and between maternal BMI and adverse pregnancy outcomes. There is no evidence that the effect of maternal BMI on outcomes is via an effect on GWG. Our analyses also cast doubt on the existence of a relationship between 'excessive' GWG and adverse pregnancy outcomes. Our findings challenge the practice of actively managing GWG throughout pregnancy.
PURPOSE: To obtain a hair color rinse compsn. having a superior dyeing effect, hardly irritating the skin, forming a natural color after use and also having a superior conditioning effect. CONSTITUTION: This hair color rinse compsn. contains 0.01-2.0 pts.wt. one or more kinds of acid dyes, 0.01-0.5 pt.wt. one or more kinds of halogenated fluorescein dyes represented by formula I or II, (wherein X is H, Cl, Br or I, at least two of four X's are not H, Y is H, Cl or Br and M is H, Na or K), e.g. red No. 104 (phloxine B) and orange No. 201 (dibromofluorescein) and 1.0-20.0 pts.wt. disodium dimethiocone polyol sulfosuccinate having a mol.wt. of 10,000-30,000. This compsn. is preferably adjusted to pH 3.0-5.0 so as to produce a highly dyeing effect.
A process is described for the preparation of electrostatically-linked, aliphatic- or alicyclic-substituted anionic or cationic polysaccharide gels from readily available macroporous ionic polysaccharide chromatographic media. Examples of such macroporous ionic polysaccharide chromatographic media include diethylaminoethyl (DEA.E), quaternary aminoethyl (QAE) and sulfopropyl (SP) substituted polysaccharide gels. These novel gels are used for the isolation, recovery and purification of non-polar extractives using one or more extracting solvents from the group of lower alcohols, ketones, and water. The non-polar extractives may include one or more of the classes alk(en)lyresorcinols, steroid, triterpenoid, cardiac glycosides and saponins, steryl ferulates and other phenolic acid conjugates, flavonoids, polar lipids, alcohol-soluble antimicrobials, prolamines and other alcohol-soluble proteolipid complexes. The process uses hydrophobic interaction chromatography, and involves the steps of absorption, washing and recovery, wherein the extractives are absorbed and desorbed in the presence of and as a result of the concentration and selection of the organic solvent. The method further includes the optional step of regenerating the gel matrix for further use.
FIELD: veterinary virology. SUBSTANCE: new strain Virus pestis carnivorum - "ВНИИВВиМ - 88 Деп" is obtained from vaccine strain ЭПМ by adaptation and cloning in subline of transplantable cells from green African monkey CV-1. Strain shows high reproducing capability and showing the specific cytopathogenic effect, accumulation of virus-specific antigen and virus at titers up to 5625-31620 ТЦД 50/cm 3 ,, harmless, areactivity, high immunogenic activity, absence of pollution with bacteria, fungi, mycoplasmas and foreign viruses. Strain shows genetic stability, noncontagiousness and nonreveribility. Strain can be used for preparing preparations used for diagnosis and specific prophylaxis in fur wild animal and dog diseases caused by carnivorous plague virus. EFFECT: virus strain indicated above.
BACKGROUND: Most lower extremity defects and minor bone defect wounds requiring a free flap are treatable with soft-tissue flaps, whereas large bone defect wounds are treated with bone-based flaps. This study aimed to compare bone-based and soft-tissue-free flaps in terms of operative procedures and postoperative complications, including long-term outcomes of lower extremity reconstruction.
METHODS: This two-center retrospective cohort study collected data from all lower-extremity reconstructions with free flaps performed between March 2014 and February 2022; the level of evidence is considered to be therapeutic level III. We investigated the operative procedure and postoperative complications classified as being related to either bone-based or soft-tissue flaps. The data were further classified into the trauma and non-trauma groups and the long-term postoperative outcomes of patients who were followed up for ≥12 months were analyzed.
RESULTS: A total of 122 free flaps were included: 29 bone-based flaps (1 scapular and 28 fibular flaps) and 93 soft-tissue flaps (22 muscle-based and 71 fasciocutaneous flaps). There was no significant difference in postoperative complications, including long-term outcomes, between the free flap types, regardless of etiology. Vein grafts were used more often for bone-based flaps than for soft-tissue flaps (20.7% vs. 7.5%; p = 0.045). The donor veins of bone-based flaps were more often anastomosed to superficial veins than were those of soft-tissue flaps (37.9% vs. 10.8%; p < 0.001).
CONCLUSIONS: Using bone-based free flaps resulted in no significant differences in postoperative complications, including long-term outcomes, despite involving more complicated operative procedures than soft-tissue flaps. Thus, the use of vein grafts and anastomosis to the superficial venous system of the vascularized fibula graft may help avoid flap-related complications in bone-based free flaps.
Systems, methods, computer-readable media, and graphical user interfaces for facilitating an audit trail are provided. Integrated data capture workflows are initiated from within an electronic medical record (EMR). Selections of data from the EMR are received to make available to case report forms. The case report forms are populated with the selections of data and associated audit information. Selections of alternate results are received. The case report forms are populated with the alternate results and associated alternate result audit information. The case report forms are stored.
The Autoimmune Lymphoproliferative Syndrome (ALPS) is an inherited disorder associated with defective lymphocyte apoptosis, which is clinically characterized by prominent nonmalignant lymphadenopathy, hepatosplenomegaly, and overt autoimmune diseases such as hemolytic anemia, autoimmune thrombocytopenia, and neutropenia. Additionally, ALPS patients have a significantly increased risk of developing non-Hodgkin lymphoma (NHL) and Hodgkin lymphoma (HL). The diagnosis of lymphoma is particularly troublesome in ALPS because many ALPS manifestations overlap with clinical features suggestive of lymphoma. Therefore, individuals with ALPS may undergo repeated biopsies during the course of the disease. Fluorodeoxyglucose positron emission tomography combined with computed tomography (FDG-PET/CT) is a noninvasive test that may help us discriminate benign from malignant lymphadenopathy in patients with ALPS.

For patients with ALPS and clinical symptoms suggestive of lymphoma, such as a sudden increase in focal lymphadenopathy and/or systemic B symptoms associated with lymphoma, we want to investigate whether FDG-PET/CT is useful in determining a plan of action by assisting in locating the most active lymph node and determining whether a surgical biopsy is warranted. Under this protocol, FDG-PET/CT scans will be done to rule out lymphoma. A lymph node biopsy may be necessary to determine the pathology of the lymph node and will not be done for research purposes alone.
Prior to entering the warm environmental conditions the participant will receive lidocaine intranasally at a dose no higher than 3 mg per kilogram body mass. This dose will be given only once.
BACKGROUND AND OBJECTIVE: The EV-302 trial found that the combination of enfortumab vedotin (EV) with pembrolizumab significantly improved survival for patients with metastatic urothelial carcinoma (mUC). However, given the high cost of the drugs, there is a need to assess its value by considering both efficacy and cost. This study assessed the cost-effectiveness of EV plus pembrolizumab as a first-line treatment for patients with mUC from the perspective of U.S. payers.
METHODS: A Markov model was developed to compare the lifetime costs and effectiveness of EV in combination with pembrolizumab with chemotherapy in the treatment of mUC patients from U.S. payer perspective. Life-years (LYs), quality-adjusted LYs (QALYs), and lifetime costs were estimated. One-way, two-way and probabilistic sensitivity analyses were conducted to evaluate model uncertainty. Additionally, subgroup analyses were performed.
RESULTS: Compared to chemotherapy, the combination of EV and pembrolizumab provided an additional 2.10 LYs and 1.72 QALYs, at an incremental cost of $962,240.8 per patient. The incremental cost-effectiveness ratio (ICER) is $558,973 per QALY. Subgroup analysis indicated that patients ineligible for cisplatin treatment had a lower ICER compared to those who were eligible for cisplatin.
CONCLUSIONS: From the perspective of US payers, at a willingness-to-pay threshold of $150,000 per QALY, the combination of EV and pembrolizumab is estimated to not be cost-effective compared to traditional chemotherapy in the first-line treatment of mUC patients.
This is a single blind interventional study with a post design using a convenience sample of patients undergoing a Nuclear Medicine Stress Test. The patient selection and intervention will be randomized in order to ensure a high validity study. The interventional treatment used will be a ethyl chloride mist spray manufactured by the Gebauer Company. The placebo spray that will be used is manufactured by BioLogic Aqua Research Technologies International Inc. The spray is called Nature's Tears Mist and is a sterile water. The patient's for this study are required to have intravenous cannulation (IV) access. This is a painful and invasive procedure in which a vapocoolant may confer benefit for the relief of pain.
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

The data described below reflect exposure in controlled clinical trials involving over 100 patients treated for functional bowel/irritable bowel syndrome with dicyclomine hydrochloride at initial doses of 160 mg daily (40 mg four times a day).

In these trials most of the side effects were typically anticholinergic in nature and were reported by 61% of the patients. Table 1 presents adverse reactions (MedDRA 13.0 preferred terms) by decreasing order of frequency in a side-by-side comparison with placebo.

Nine percent (9%) of patients were discontinued from dicyclomine hydrochloride because of one or more of these side effects (compared with 2% in the placebo group). In 41% of the patients with side effects, side effects disappeared or were tolerated at the 160 mg daily dose without reduction. A dose reduction from 160 mg daily to an average daily dose of 90 mg was required in 46% of the patients with side effects who then continued to experience a favorable clinical response; their side effects either disappeared or were tolerated.
NEW MATERIAL:3-(R)-4-(R)-Dihydroxy-5-(R)-hydroxymethyl-1-pyrroline expressed by formula I and a salt thereof. USE:A medicine, immunological regulator or hypoglycemic agent. PREPARATION:A strain, belonging to the genus Nectria and capable of producing the purroline compound expressed by formula I, e.g. Nactria lucida F-4490 strain, is fermented in a nutrient culture medium to give the aimed compound expressed by formula I or a compound expressed by formula VII (R<1>-R<3> and R<5> are different protecting groups of OH group or R<1> and R<2> together form a protecting group of the adjacent OH group) is subjected to introduction reaction of amino group to form a compound expressed by formula VI, and a protecting group R4 of the amino group is introduced thereinto. The resultant compound is then subjected to elimination reaction of the protecting group of the OH group to afford a compound expressed by formula IV. Oxidative cleavage of the glycol part thereof is then carried out to afford a compound expressed by formula III, which is further subjected to the elimination reaction of the protecting group of the OH group to give a compound expressed by formula II, which is further subjected to elimination reaction of the protecting groups of the amino group and formyl group to give the aimed compound expressed by formula I.
The patients in control group take 2L PEG the day before the examination, fast at dinner (patients without diabetes) and eat without residue (patients with diabetes). Patients take 2L PEG again in the morning of the examination day, and fasted at breakfast and lunch of the day.
Mercaptopurine is a nucleoside metabolic inhibitor, The chemical name is 6H-purine-6-thione, 1,7-dihydro-, monohydrate. The molecular formula is C5H4N4S • H2O and the molecular weight is 170.20. Its structural formula is:

Mercaptopurine is a yellow, crystalline powder. Mercaptopurine is practically insoluble in water and in ether. It has a pKa of 7.8, an average tapped density of 1.0 g/mL and average bulk density of 0.85 g/mL. It dissolves in solutions of alkali hydroxides.

Mercaptopurine Tablets is available for oral use. Each scored tablet contains 50 mg mercaptopurine and the following inactive ingredients: corn starch, pregelatinized, potato starch, lactose, magnesium stearate and stearic acid.
A pre-test was administered to all students. In the pre-test application, the Descriptive Information Form, General Health Questionnaire-28, Pittsburgh Sleep Quality Index and Perceived Stress Scale were applied. Experimental and control groups were formed randomly among the students who filled all the scales. Communication groups were established for the students in both groups without being told which group they belonged to. Considering the hours suitable for the experimental group, 8 sessions of laughter therapy were applied for an average of 45 minutes. At the end of the therapy in the last session, a post-test was administered to all of the students. In the post-test application, the Descriptive Information Form, General Health Questionnaire-28, Pittsburgh Sleep Quality Index, and Perceived Stress Scale were applied.
To observe the expression changes of P2 protein in cochlear spiral ganglion cells before and after noise injury, and to explore the relationship between the changes of purinergic receptors in spiral ganglion cells and noise-induced hearing loss, so that the signal transduction of purinergic receptors can be used to treat SNHL The target point provides a theoretical basis. The experimental animals were randomly divided into normal and experimental groups. The experimental group was given 120 dB white noise continuous exposure for 10 days and 3 h a day. The auditory brainstem response was measured before and after the noise exposure. After the noise exposure, the two groups of animals were collected. Do immunofluorescence staining, western blot, fluorescence real-time quantitative PCR to observe the expression of P2 protein. The average hearing threshold of the animals in the experimental group increased to 38.75 ± 6.44 dB SPL after 7 days of noise exposure, and the high-frequency hearing loss was lower and severe; the average hearing threshold increased to 54.38 ± 6.80 dB SPL after 10 days of noise exposure, and the hearing loss at 4 k Hz was relatively high. Light; Frozen sections of cochlear spiral ganglion cells and staining of isolated spiral ganglion cells found that P2X2, P2X3, P2X4, P2X7, P2Y2, and P2Y4 proteins were all expressed in cochlear spiral ganglion cells before noise exposure. Among them, P2X3 expression increased and P2X4, the down-regulation of P2Y2 expression was statistically significant (P < 0.05); Western blot and real-time quantitative PCR detection results showed that the expression of P2X3 was significantly increased after noise exposure than before noise exposure (P < 0.05), and P2X4 and P2Y2 were expressed after noise exposure The amount was significantly lower than before noise exposure (P < 0.05). (Figure. 4). After noise exposure, the expression of P2 protein is upregulated or downregulated. By affecting the Ca2+ cycle, the transmission of sound signals to the auditory center is blocked, which provides a theoretical basis for the signal transduction of purinergic receptors to become a target for the treatment of SNHL.